Delaware | 001-36783 | 20-1450200 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
2130 W. Holcombe Blvd., Ste. 800 Houston, TX | 77030 | |||
(Address of principal executive offices) | (Zip Code) |
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Exhibit No. | Description | |
99.1 | Press Release dated August 8, 2017. |
Bellicum Pharmaceuticals, Inc. | ||||||
Dated: August 8, 2017 | By: | /s/ Alan A. Musso | ||||
Alan A. Musso | ||||||
Chief Financial Officer and Treasurer | ||||||
Principal Financial and Accounting Officer |
Exhibit No. | Description | |
99.1 | Press Release dated August 8, 2017. |
• | Data Update Suggests BPX-501 Improves Outcomes of Haploidentical Stem Cell Transplants |
• | Positive Clinical Results of BPX-501 in Pediatric Leukemias |
• | European BP-004 Pivotal Clinical Trial Progressing |
• | Company Clarifies U.S. Clinical Development Strategy |
• | Phase 1 BPX-601 Clinical Trial Continues |
• | Phase 1 BPX-701 Clinical Trial Continues |
• | Addition of Chief Business Officer to Expand Partnership Opportunities |
• | In April, Bellicum reported positive preclinical data at AACR on its novel dual-switch technology incorporated into CAR T and TCR constructs, an approach offering the possibility of both activating cells to enhance efficacy and eliminating them to manage toxicity. Bellicum is working to incorporate its dual-switch technology into future CAR T and TCR product candidates. |
• | The Company continues to work with academic collaborators to explore the applicability of CaspaCIDe in CD19 CARs, the first of which is expected to enter the clinic in the second half of this year in patients with B-cell malignancies. |
BELLICUM PHARMACEUTICALS, INC. | ||||||||||||||||
Unaudited Condensed Consolidated Balance Sheets | ||||||||||||||||
(in thousands) | ||||||||||||||||
June 30, 2017 | December 31, 2016 | |||||||||||||||
Current Assets: | ||||||||||||||||
Cash and cash equivalents | $ | 75,148 | $ | 33,140 | ||||||||||||
Investment securities, available-for-sale, short-term | 55,081 | 70,632 | ||||||||||||||
Prepaid expenses and other current assets | 2,896 | 1,838 | ||||||||||||||
Non-Current Assets: | ||||||||||||||||
Investment securities, available-for-sale, long-term | 4,405 | — | ||||||||||||||
Property and equipment, net | 25,458 | 16,504 | ||||||||||||||
Restricted cash | 4,383 | 9,640 | ||||||||||||||
Other assets | 353 | 283 | ||||||||||||||
Total assets | $ | 167,724 | $ | 132,037 | ||||||||||||
Current Liabilities: | ||||||||||||||||
Accounts payable and other accrued liabilities | 12,267 | 12,986 | ||||||||||||||
Current maturities of long-term debt | 3,412 | 1,787 | ||||||||||||||
Other current liabilities | 283 | 340 | ||||||||||||||
Long-Term Liabilities: | ||||||||||||||||
Long-term debt | 27,116 | 18,436 | ||||||||||||||
Other liabilities, net of current portion | 1,939 | 1,914 | ||||||||||||||
Total Stockholders' Equity | 122,707 | 96,574 | ||||||||||||||
Total liabilities and stockholders' equity | $ | 167,724 | $ | 132,037 | ||||||||||||
BELLICUM PHARMACEUTICALS, INC. | ||||||||||||||||
Unaudited Condensed Consolidated Statements of Operations | ||||||||||||||||
(in thousands, except share and per share amounts) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||||
Grant Revenues | $ | — | $ | 101 | $ | 128 | $ | 193 | ||||||||
Operating Expenses: | ||||||||||||||||
Research and development | 17,959 | 12,031 | 33,254 | 22,889 | ||||||||||||
License fees | 343 | 150 | 698 | 280 | ||||||||||||
General and administrative | 5,486 | 4,179 | 11,413 | 8,463 | ||||||||||||
Total operating expenses | 23,788 | 16,360 | 45,365 | 31,632 | ||||||||||||
Operating loss | (23,788 | ) | (16,259 | ) | (45,237 | ) | (31,439 | ) | ||||||||
Interest expense, net | (669 | ) | (250 | ) | (1,193 | ) | (145 | ) | ||||||||
Net loss attributable to common shareholders | $ | (24,457 | ) | $ | (16,509 | ) | $ | (46,430 | ) | $ | (31,584 | ) | ||||
Net loss per share attributable to common shareholders, basic and diluted | $ | (0.74 | ) | $ | (0.61 | ) | $ | (1.54 | ) | $ | (1.17 | ) | ||||
Weighted-average common shares outstanding, basic and diluted | 33,074,463 | 26,910,284 | 30,201,116 | 26,896,405 | ||||||||||||
(_$&E>'[=ONRZI>QVRG\
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M.\93E1-+*D>$R!E AW#(W#O^I5%% !1110 4444 %%NZVBCS=>U^%+N[=^[*6&V(=L1A1
MCKGJ?<-5\(:%KM@+#4M%T[4+$+L%K=6L
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end